Daraxonrasib demonstrated unprecedented survival improvements over standard chemotherapy in advanced pancreatic cancer in the phase 3 RASolute 302 trial.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Daraxonrasib Shows "Unprecedented" Survival in Pretreated Pancreatic Cancer | CancerNetwork
Phase 3 Trial phase
RASolute 302 Study name
Metastatic PDAC Cancer type
Improved Median OS Outcome